pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Nephrology · news · pharmadog
← back to Nephrology
News · Nephrology
131
stories
15h
Cancer vaccine win restores Wall Street’s faith in Moderna
biopharma dive
19h
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
biospace
21h
Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
fiercebiotech
22h
Reduce protein to increase longevity? Nutrition experts say that’s a bad idea
stat
1d
7 biopharma M&A deals where layoffs followed
biospace
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
1d
Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
biospace
1d
Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
biopharma dive
2d
STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
stat
3d
Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxact
biospace
6d
Skye and Redx form new entity with $125M to advance fibrosis assets
fiercebiotech
6d
Pressure piles on Amgen after EU pulls Tavneos, flags 'serious breaches' in pivotal study
biospace
7d
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale
biospace
8d
BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
biospace
8d
Boulevard starts up with $65M to pursue targeted autoimmune drugs
biopharma dive
8d
Opinion: Climate change is making people with chronic illness even sicker
stat
9d
Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs
fiercebiotech
10d
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
biospace
13d
BioMarin axes $270M rare disease asset after missing phase 3 endpoint
fiercebiotech
14d
U.S. moves to shut a Kentucky organ donation group, citing safety failures
stat
14d
With $263M, LifeMine unearths a new drug for organ transplants
biopharma dive
14d
LifeMine raises $263M in mission to improve organ transplant aftercare
biospace
14d
Opinion: STAT+: Stop asking if AI is good for medicine
stat
15d
‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E
fiercebiotech
15d
Attovia adds to biotech IPO momentum with $289M offering
biopharma dive
15d
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
biospace
15d
MRI is standard for diagnosing prostate cancer in most western countries. But most U.S. men don’t get them
stat
16d
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
fiercebiotech
16d
Otsuka succeeds with kidney drug; BioNTech downgrades revenue projection
endpoints
16d
Vertex unfazed by competitive IgAN space as FDA verdict looms
biospace
← prev
page 1 of 5
next →
